TargetMol
![]() |
||
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global small molecule suppliers with over 5000 inhibitors and 80+ compound libraries in stock. TargetMol offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, activator, APIs and natural compounds for laboratory and scientific use. Website : www.targetmol.com |
![SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques](https://www.clinisciences.com/it/upload/thumbs/therapeutic-covid-19-ubascr-dcbe47.jpg)
SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques
Acalabrutinib (or Calquence) is an inhibitor of Bruton's tyrosine kinase (BTK). By inactivating the BTK, acalabrutinib prevents activation of the B-cell antigen receptor (BCR) signaling pathway. The B cell activation and downstream survival pathways of B-cells are thus inhibited and, as a result, the growth of malignant B cells that overexpress B-cells is inhibited. It is for this mode of action that acalabrutinib is used in the treatment of certain types of non-Hodgkin's lymphoma such as mantle cell lymphoma.
A clinical trial is planned to evaluate the effect of acalabrutinib (Calquence) on the exaggerated immune response in patients with severe coronavirus 2019 infection (Covid-19). This clinical study was based on preliminary scientific and clinical data on the BTK pathway and its role in the production of inflammatory cytokines. The purpose of the study was to evaluate the efficacy of acalabrutinib in reducing mortality and ventilation support requirements for patients with severe symptoms of Covid-19.
Risultati della ricerca : 8 prodotto(i) trovato(i)
Limita la ricerca :
RUOCE / IVD
- Biochemicals 8
Cat#
Descrizione
Cond.
Priced
‹
›